Document:

Exhibit 4.3

 

WARRANT 

 

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS
OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL
AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

	No._______	February 26, 2015

 

Bionik Laboratories Corp.

 

Common Stock Purchase Warrant

 

 

 

THIS CERTIFIES
THAT, for value received, [NAME], or his/her/our registered assigns (the “Purchaser”), is entitled to
subscribe for and purchase from Bionik Laboratories Corp., a Delaware corporation (the “Company”), at any
time commencing on February 26, 2015 and expiring on February 26,  2019 (the “Warrant Exercise Term”), the
Shares at the Exercise Price (each as defined in Section 1 below).

 

This Warrant is issued
in connection with the Company’s private offering solely to accredited investors of Units in accordance with, and subject
to, the terms and conditions described in the Subscription Agreement, dated as of even date herewith (the “Subscription
Agreement”).

 

This Warrant is subject
to the following terms and conditions:

 

1.            Shares.
The Purchaser has, subject to the terms set forth herein, the right to purchase, at any time during the Warrant Exercise Term,
up to [_NUMBER OF SHARES_] shares (the “Shares”) of the Company’s common stock, par value $0.001 (“Common
Stock”), at a per share exercise price of $1.40 (the “Exercise Price”). The Exercise Price is subject
to adjustment as provided in Section 3 hereof.

 

2.            Exercise
of Warrant.

 

(a)          Exercise.
This Warrant may be exercised by the Purchaser at any time during the Warrant Exercise Term, in whole or in part, by delivering
the notice of exercise attached as Exhibit A hereto (the “Notice of Exercise”), duly executed by the
Purchaser to the Company at its principal office, or at such other office as the Company may designate, accompanied by payment,
in cash or by wire transfer of immediately available funds or by check payable to the order of the Company, or via cashless exercise
(if permitted) of the amount obtained by multiplying the number of Shares designated in the Notice of Exercise by the Exercise
Price (the “Purchase Price”). For purposes hereof, “Exercise Date” shall mean the date on
which all deliveries required to be made to the Company upon exercise of this Warrant pursuant to this Section 2(a) shall have
been made.

 

    	 

    	 

    

 

(b)          Cashless
Exercise. In addition to the provisions of Section 2(a) above, at any time prior to the effectiveness of certain resale registration
statement described in the Confidential Private Placement Memorandum, dated September 10, 2014, as amended and/or supplemented,
in connection with the Subscription Agreement (the “PPM”) or if such registration statement is no longer effective
but should be in accordance with the Registration Rights attached as Annex A to the Subscription Agreement (the “Registration
Rights Agreement”), the Purchaser may, in its sole discretion, exercise all or any part of this Warrant in a “cashless”
or “net-issue” exercise (a “Cashless Exercise”) by delivering to the Company (1) the Notice of Exercise
and (2) the original Warrant, pursuant to which the Purchaser shall surrender the right to receive upon exercise of this Warrant
the full number of Warrant Shares set forth in Section 1 hereof and instead, without cash payment, shall receive a number of Warrant
Shares calculated by using the following formula:

 

	 	X	=	Y (A - B)
	 		 	A

 

	with:	X =	the number of Warrant Shares to be issued to the Purchaser
	 	 	 
	 	Y =	the number of Warrant Shares with respect to which the Warrant is being exercised
	 	 	 
	 	A =	the fair value per share of Common Stock on the date of exercise of this Warrant
	 	 	 
	 	B =	the then-current Exercise Price of the Warrant

 

Solely for the purposes
of this paragraph 2(b), “fair value” per share of Common Stock shall mean (A) the average of the closing sales prices,
as quoted on the primary national or regional stock exchange on which the Common Stock is listed, or, if not listed, on the Nasdaq
Market if quoted thereon, or, if not listed or quoted, the OTC Bulletin Board (or any tier of the OTC Markets) if quoted thereon,
on the twenty (20) consecutive Trading Days (as defined below) immediately preceding the date on which the Notice of Exercise is
deemed to have been sent to the Company, or (B) if the Common Stock is not publicly traded as set forth above, as reasonably and
in good faith determined by the Board of Directors of the Company as of the date which the Notice of Exercise is deemed to have
been sent to the Company.

 

For purposes of Rule
144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless
exercise transaction shall be deemed to have been acquired by the Purchaser, and the holding period for such shares shall be deemed
to have commenced, on the date this Warrant was originally issued.

 

    	2

    	 

    

 

(c)          Redemption.
(i) All of the outstanding Warrants (but not less than all) may be redeemed, at the option of the Company, at any time while they
are exercisable and prior to their expiration upon notice to the Purchaser at the price of $0.001 per Warrant (the “Redemption
Price”), provided that the VWAP (as defined below) of the Common Stock is 200% of the exercise price or more for
20 consecutive Trading Days prior to the date on which notice of the redemption is given and provided that there is an effective
registration statement covering the Common Stock issuable upon exercise of the Warrants, available throughout the 30-day period
after the Redemption Date (as defined below)(unless the Company requires a cashless exercise as provided below). “VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market (as defined below), the daily volume weighted average price of the Common Stock for such date (or
the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is then
quoted on the OTC Bulletin Board, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and
if prices for the Common Stock are then reported on OTC Markets, Inc. (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the
fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers
of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company. “Trading Day” means a day on which the principal Trading Market is open for trading.
“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the New York Stock Exchange (or any successors to any of the foregoing), the OTC Bulletin Board or OTC Markets, Inc. (ii)
In the event that the Company elects to redeem all of the Warrants, the Company’s board of directors has the right to require
the Purchaser to exercise the Warrants on a “cashless basis,” by surrendering the Warrants for that number of shares
of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the
Warrants, multiplied by the difference between the Exercise Price and the average VWAP for 20 consecutive Trading Days prior to
the date on which the notice of the redemption is sent to Purchaser (“Average VWAP”) by (y) the Average VWAP.
(iii) The Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be
mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date to
the Purchasers to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the
manner herein provided shall be conclusively presumed to have been duly given whether or not the Purchaser received such notice.
(iv) The notice of redemption shall contain the information necessary to calculate the number of shares of Common Stock to be received
upon exercise of the Warrants, including the VWAP and Average VWAP calculations. On and after the Redemption Date, the record holder
of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.

 

(d)          Issuance
of Certificates. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section
2(a) or 2(b) hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Purchaser (i) a
certificate or certificates for the number of validly issued, fully paid and non-assessable Shares to which the Purchaser shall
be entitled upon such exercise and, if applicable, (ii) a new warrant of like tenor to purchase all of the Shares that may be purchased
pursuant to the portion, if any, of this Warrant not exercised by the Purchaser. The Purchaser shall for all purposes hereof be
deemed to have become the Purchaser of record of such Shares on the date on which the Notice of Exercise and payment of the Purchase
Price in accordance with Section 2(a) or 2(b) hereof were delivered and made, respectively, irrespective of the date of delivery
of such certificate or certificates, except that if the date of such delivery, notice and payment is a date when the stock transfer
books of the Company are closed, such person shall be deemed to have become the holder of record of such Shares at the close of
business on the next succeeding date on which the stock transfer books are open. Warrant Shares purchased hereunder shall be transmitted
by the transfer agent to the Holder by crediting the account of the Holder’s prime broker with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such
system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by the Holder or (B) the shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the
date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise and (B) surrender
of this Warrant (if required).

 

    	3

    	 

    

 

(e)          Taxes.
The issuance of the Shares upon the exercise of this Warrant, and the delivery of certificates or other instruments representing
such Shares, shall be made without charge to the Purchaser for any tax or other charge of whatever nature in respect of such issuance
and the Company shall bear any such taxes in respect of such issuance.

 

3.            Adjustment
of Exercise Price and Number of Shares.

 

(a)          Adjustment
for Reclassification, Consolidation or Merger. If while this Warrant, or any portion hereof, remains outstanding and unexpired
there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision of
shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other
entity in which the Company shall not be the surviving entity, or a reverse merger (other than the reverse merger described in
the PPM, in which case this Warrant will represent a warrant in such public entity on the terms hereof) in which the Company shall
be the surviving entity but the shares of the Company’s capital stock outstanding immediately prior to the merger are converted
by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer
of the Company’s properties and assets as, or substantially as, an entirety to any other corporation or other entity in one
transaction or a series of related transactions, then, as a part of such reorganization, recapitalization, merger, consolidation,
sale or transfer, unless otherwise directed by the Purchaser, all necessary or appropriate lawful provisions shall be made so that
the Purchaser shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified herein and upon
payment of the Exercise Price then in effect, the greatest number of shares of capital stock or other securities or property that
a holder of the Shares deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, recapitalization,
merger, consolidation, sale or transfer if this Warrant had been exercised immediately prior to such reorganization, recapitalization,
merger, consolidation, sale or transfer, all subject to further adjustment as provided in this Section 3. If the per share consideration
payable to the Purchaser for Shares in connection with any such transaction is in a form other than cash or marketable securities,
then the value of such consideration shall be determined in good faith by the Company’s Board of Directors (the “Board
of Directors”). The foregoing provisions of this paragraph shall similarly apply to successive reorganizations, recapitalizations,
mergers, consolidations, sales and transfers and to the capital stock or securities of any other corporation that are at the time
receivable upon the exercise of this Warrant. In all events, appropriate adjustment shall be made in the application of the provisions
of this Warrant with respect to the rights and interests of the Purchaser after the transaction, to the end that the provisions
of this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any shares or other property
deliverable or issuable after such reorganization, recapitalization, merger, consolidation, sale or transfer upon exercise of this
Warrant.

 

(b)          Adjustments
for Split, Subdivision or Combination of Shares. If the Company shall at any time subdivide (by any stock split, stock dividend,
recapitalization, reorganization, reclassification or otherwise) the shares of Common Stock subject to acquisition hereunder, then,
after the date of record for effecting such subdivision, the Exercise Price in effect immediately prior to such subdivision will
be proportionately reduced and the number of shares of Common Stock subject to acquisition upon exercise of the Warrant will be
proportionately increased. If the Company at any time combines (by reverse stock split, recapitalization, reorganization, reclassification
or otherwise) the shares of Common Stock subject to acquisition hereunder, then, after the record date for effecting such combination,
the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of shares of
Common Stock subject to acquisition upon exercise of the Warrant will be proportionately decreased.

 

    	4

    	 

    

 

(c)          Adjustments
for Dividends in Stock or Other Securities or Property. If while this Warrant, or any portion hereof, remains outstanding and
unexpired, the holders of any class of securities as to which purchase rights under this Warrant exist at the time shall have received
or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without
payment therefor, other or additional stock or other securities or property (other than cash) of the Company by way of dividend,
then and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of such class of
security receivable upon exercise of this Warrant, and without payment of any additional consideration therefor, the amount of
such other or additional stock or other securities or property (other than cash) of the Company that such holder would hold on
the date of such exercise had it been the holder of record of the class of security receivable upon exercise of this Warrant on
the date hereof and had thereafter, during the period from the date hereof to and including the date of such exercise, retained
such shares and/or all other additional stock available to it as aforesaid during said period, giving effect to all adjustments
called for during such period by the provisions of this Section 3.

 

(d)          Adjustment
of Exercise Price Upon Issuance of Additional Shares of Common Stock. If while this Warrant, or any portion hereof, remains
outstanding and unexpired, the Company shall issue Additional Shares of Common Stock (as hereinafter defined) without consideration
or for a consideration per share less than the then-applicable Exercise Price, then and in such event, such Exercise Price shall
be reduced, concurrently with such issue, to a price (calculated to the nearest cent) determined by multiplying the then-applicable
Exercise Price by a fraction, (i) the numerator of which shall be the number of shares of Common Stock issued and outstanding immediately
prior to such issuance plus the quotient obtained by dividing (x) the aggregate consideration received by the Company for the total
number of Additional Common Stock so issued by (y) the Exercise Price, and (ii) the denominator of which shall be the number
of shares of the Common Stock issued and outstanding immediately prior to such issuance plus the number of Additional Shares of
Common Stock so issued.

 

For the purposes hereof
“Additional Shares of Common Stock” shall mean all shares of Common Stock, or options, rights, warrants to subscribe
for Common Stock, or securities convertible into or exchangeable for shares of Common Stock, actually issued by the Company on
or after the date hereof, other than shares of Common Stock or securities convertible into or exchangeable for shares of Common
Stock issued at any time:

 

(i)          upon
exercise of the Warrants;

 

(ii)         upon
the completion of the Reverse Merger in connection with the Offering.

 

(iii)        pursuant
to the exercise of options, warrants or other common stock purchase rights issued (or to be issued) to employees, officers or directors
of, or consultants or advisors to, or any strategic ally of or investor in, the Company pursuant to any stock purchase plan, stock
option plan, equity incentive plan or other plan or arrangement approved by the Board of Directors (or the Compensation Committee
thereof) at any time;

 

(iv)        pursuant
to the exercise of options, warrants or any evidence of indebtedness, shares of capital stock (other than Common Stock) or other
securities convertible into or exchangeable for Common Stock (“Convertible Securities”) outstanding as of the
date of the issuance of this Warrant;

 

(v)         in
connection with the acquisition of all or part of another entity by stock acquisition, merger, consolidation or other reorganization,
or by the purchase of all or part of the assets of such other entity (including securities issued to persons formerly employed
by such other entity and subsequently hired by the Company and to any brokers or finders in connection therewith);

 

    	5

    	 

    

 

(vi)        bona
fide commercial partners, or lessors in connection with credit arrangements, equipment financings or similar transactions approved
by the Board of Directors; or

 

(vii)       in
connection with the Company’s acquisition, joint-venture, licensing or business transaction of intellectual property assets
from any individuals or entities approved by the Board of Directors.

 

Upon each adjustment
of the Exercise Price pursuant to the provisions of this Section 3(d), the number of Shares issuable upon exercise of this Warrant
shall be adjusted by multiplying a number equal to the Exercise Price in effect immediately prior to such adjustment by the number
of Shares issuable upon exercise of this Warrant immediately prior to such adjustment and dividing the product so obtained by the
adjusted Exercise Price.

 

(e)          Notice
of Adjustments. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Shares purchasable
upon the exercise of this Warrant, then, and in each such case, the Company, within 30 days thereafter, shall give written notice
thereof to the Purchaser at the address of such Purchaser as shown on the books of the Company, which notice shall state the Exercise
Price as adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of this Warrant,
setting forth in reasonable detail the method of calculation of each.

 

4.            Notices.
All notices, requests, consents and other communications required or permitted under this Warrant shall be in writing and shall
be deemed delivered (i) three business days after being sent by registered or certified mail, return receipt requested, postage
prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business
day delivery or (iii) on the business day of delivery if send by facsimile transmission, in each case to the intended recipient
as set forth below:

 

If to the Company to:

 

Bionik Laboratories Corp.

10 Dundas St. E. Office AMC-B202

Toronto, ON M5B 2G9

Attention: Peter Bloch

Facsimile:

 

With a copy (that shall not constitute notice)
to:

 

Ruskin Moscou Faltischek, P.C.

East Tower, 15th Floor

1425 RXR Plaza

Uniondale, New York 11556

Attention: Stephen E. Fox, Esq.

Facsimile: (516) 663-6780

 

If to the Purchaser
at its address as furnished in the Subscription Agreement.

 

Either party may give
any notice, request, consent or other communication under this Warrant using any other means (including personal delivery, messenger
service, facsimile transmission, first class mail or electronic mail), but no such notice, request, consent or other communication
shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Either party
may change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the
other party notice in the manner set forth in this Section 4.

 

    	6

    	 

    

 

5.            Legends.
Each certificate evidencing the Shares issued upon exercise of this Warrant shall be stamped or imprinted with a legend substantially
in the following form:

 

THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES
LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL
AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

6.            Removal
of Legend. Upon request of a holder of a certificate with the legends required by Section 5 hereof and subject to Section 3(f)
of the Registration Rights Agreement, the Company shall issue to such holder a new certificate therefor free of any transfer legend,
if, with such request, the Company shall have received an opinion of counsel satisfactory to the Company in form and substance
to the effect that any transfer by such holder of the Shares evidenced by such certificate will not violate the Act or any applicable
state securities laws.

 

7.            Fractional
Shares. No fractional Shares will be issued in connection with any exercise hereunder. Instead, the Company shall round up,
as nearly as practicable to the nearest whole Share, the number of Shares to be issued.

 

8.            Rights
of Stockholders. Except as expressly provided in Section 3(c) hereof, the Purchaser, as such, shall not be entitled to vote
or receive dividends or be deemed the holder of the Shares or any other securities of the Company that may at any time be issuable
on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Purchaser, as such,
any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted
to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization,
issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive
notice of meetings, or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof
shall have been issued, as provided herein.

 

9.            Miscellaneous.

 

(a)          This
Warrant and disputes arising hereunder shall be governed by and construed and enforced in accordance with the laws of the State
of Delaware applicable to agreements made and to be performed wholly within such State, without regard to its conflict of law rules.

 

(b)          The
headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

    	7

    	 

    

 

(c)          The
covenants of the respective parties contained herein shall survive the execution and delivery of this Warrant.

 

(d)          The
terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company
and of the Purchaser and of the Shares issued or issuable upon the exercise hereof.

 

(e)          This
Warrant and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
parties with regard to the subject hereof.

 

(f)          The
Company shall not, by amendment of the Certificate of Incorporation or Bylaws, or through any other means, directly or indirectly,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith assist
in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect
the rights of the Purchaser contained herein against impairment.

 

(g)          Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount
to the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at its expense,
will execute and deliver to the Purchaser, in lieu thereof, a new Warrant of like date and tenor.

 

(h)          This
Warrant and any provision hereof may be amended, waived or terminated only by an instrument in writing signed by the Company and
the Purchaser.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK;
SIGNATURE PAGE FOLLOWS]

 

    	8

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be signed by its duly authorized officer.

 

	 	Bionik Laboratories Corp.
	 	 	 
	 	By:	 
	 	 	Name: Peter Bloch
	 	 	Title:  Chief Executive Officer

 

    	9Exhibit 10.1 

 

INVESTMENT AGREEMENT

 

AMONG

 

BIONIK LABORATORIES INC.

AND

BIONIK ACQUISITION INC.

AND

BIONIK LABORATORIES CORP. (FORMERLY KNOWN AS DRYWAVE TECHNOLOGIES, INC.)

 

February 26, 2015

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	Article 1 INTERPRETATION	2
	 	 	 
	1.1	Definitions	2
	 	 	 
	1.2	Interpretation Not Affected by Headings, etc.	4
	 	 	 
	1.3	Number, etc.	4
	 	 	 
	1.4	Date for Any Action	4
	 	 	 
	1.5	Currency	4
	 	 	 
	1.6	Knowledge	4
	 	 	 
	1.7	Meanings	4
	 	 	 
	Article 2 PURCHASED SHARE SUBSCRIPTION, LOAN AND ISSUANCE OF PROMISSORY NOTE	4
	 	 	 
	2.1	Subscription for Purchased Shares	4
	 	 	 
	2.2	Loan and Issuance of Promissory Note	5
	 	 	 
	2.3	Closing	5
	 	 	 
	2.4	Closing Conditions and Deliveries	5
	 	 	 
	Article 3 COVENANTS	6
	 	 	 
	3.1	Covenants of Bionik US	6
	 	 	 
	3.2	Covenants of Bionik Canada	7
	 	 	 
	Article 4 REPRESENTATIONS AND WARRANTIES	7
	 	 	 
	4.1	Representations and Warranties of Bionik US and Purchaser	7
	 	 	 
	4.2	Representations and Warranties of Bionik Canada	21
	 	 	 
	Article 5 RESALE RESTRICTIONS	21
	 	 	 
	5.1	Acknowledgement	21
	 	 	 
	5.2	Legend	21
	 	 	 
	Article 6 USE OF PERSONAL INFORMATION	22
	 	 	 
	6.1	Acknowledgment	22
	 	 	 
	6.2	Personal Information	22
	 	 	 
	6.3	Notification	22
	 	 	 
	Article 7 NOTICES	23
	 	 	 
	7.1	Notices	23
	 	 	 
	Article 8 GENERAL	24
	 	 	 
	8.1	Binding Effect	24
	 	 	 
	8.2	Waiver and Modification	24
	 	 	 
	8.3	Assignment	24

 

    	 

    	 

    

 

	8.4	Costs	25
	 	 	 
	8.5	Time of Essence	25
	 	 	 
	8.6	Survival	25
	 	 	 
	8.7	Governing Law	25
	 	 	 
	8.8	Severability	25
	 	 	 
	8.9	Further Assurances	25
	 	 	 
	8.10	Counterparts and Facsimile Copies	26

 

    	- ii -

    	 

    

 

INVESTMENT
AGREEMENT

 

THIS INVESTMENT
AGREEMENT made as of the 26th day of February, 2015.

 

AMONG:

 

BIONIK LABORATORIES INC., a corporation incorporated

under the laws of Canada (hereinafter called “Bionik Canada”)

 

OF THE FIRST PART

 

- and -

 

BIONIK ACQUISITION INC., a corporation incorporated
under 

the laws of Canada (hereinafter called the “Purchaser”)

 

OF THE SECOND PART

 

- and -

 

BIONIK LABORATORIES CORP. (formerly known as 

Drywave
Technologies, Inc.), a corporation incorporated under 

the laws of the State of Delaware (hereinafter called “Bionik
US”)

 

OF THE THIRD PART

 

WHEREAS using
the net proceeds from the Unit Offering (as defined below), Bionik US wishes, indirectly through the Purchaser, its wholly-owned
subsidiary, to (i) subscribe for and purchase from Bionik Canada, 100 Class 1 common shares of Bionik Canada (the “Purchased
Shares”), representing 100% of the Class 1 common shares of Bionik Canada, at a purchase price of $1.00 per Purchased
Share, and (ii) loan $0.00 to Bionik Canada in exchange for a non-interest bearing promissory note of Bionik Canada payable on
demand in an equivalent principal amount (the “Promissory Note”);

 

AND WHEREAS
the Purchased Shares and the transactions contemplated hereby are part of a larger group of transactions, including a private placement
offering of a minimum of 7,500,000 units and a maximum of 16,000,000 units of Bionik US for gross proceeds of not less than US$6,000,000
and not more than US$12,800,000 (each unit consisting of one (1) share of common stock of Bionik US (“Bionik US Shares”)
and one (1) warrant to purchase one (1) Bionik US Share (the “Unit Offering”) and a Reverse Takeover (as defined
below) of Bionik US by the shareholders of Bionik Canada, all as described in that Confidential Private Placement Memorandum of
Bionik US, dated September 10, 2014, as supplemented by that Supplement No. 1 dated January 16, 2015, as amended or supplemented
from time to time, including all attachments, schedules and exhibits thereto (the “Memorandum”);

 

    	 

    	 

    

 

AND WHEREAS
in order to effect the Reverse Takeover, an amendment to the articles of Bionik Canada will be filed immediately prior to the Closing
(as defined below), pursuant to which a reorganization of the capital of Bionik Canada will be effected, which will consist of
(A) the removal of the restrictions on the transfer of securities of Bionik Canada (B) the creation of an unlimited number of shares
of a new class of shares exchangeable on a one-for-one basis (the “Exchangeable Shares”) at any time at the
option of the holder of the Exchangeable Shares into Bionik US Shares, (C) changing all the issued and outstanding common shares
of Bionik Canada into Exchangeable Shares on the basis of 3.14576 Bionik US Shares for each Bionik Canada common share, and thereafter
cancelling the unissued common shares and (D) creating a new class of Class 1 common shares (collectively, the (“Articles
of Amendment”);

 

AND WHEREAS
upon Closing existing shareholders of Bionik Canada will receive Exchangeable Shares which will represent the right to receive
for each Exchangeable Share one Bionik US Share, resulting in an aggregate of not less than 50,000,000 Bionik US Shares and Bionik
Canada will indirectly be acquired by Bionik US (the “Reverse Takeover”);

 

AND WHEREAS
as a result of the Reverse Takeover, the shareholders of Bionik Canada will collectively through a special voting share of Bionik
US (the “Special Voting Share”) become the beneficial holders of the majority voting rights of Bionik US;

 

AND WHEREAS
the parties have entered into this Agreement to provide for the matters referred to in the foregoing recitals and for other matters
relating to the proposed Reverse Takeover;

 

NOW THEREFORE THIS
AGREEMENT WITNESSETH that in consideration of the above premises and of the covenants, agreements, representations and warranties
hereinafter contained, the parties hereto agree as follows:

 

Article 1

INTERPRETATION

 

		1.1	Definitions

 

In this Agreement, unless there
is something in the context or subject matter inconsistent therewith, the following defined terms shall have the meanings hereinafter
set forth:

 

“Agreement”,
“this Agreement”, “herein”, “hereby”, “hereof”, “hereunder”
and similar expressions mean or refer to this agreement and any amendments hereto.

 

“associate”
and “affiliate” have the respective meanings ascribed thereto in the Securities Act (Ontario).

 

“Beneficiaries”
means the registered holders from time to time of Exchangeable Shares, other than Bionik US and any subsidiary of Bionik US.

 

“Bionik
US Special Voting Share” means the special voting share in the capital of Bionik US which entitles the holder of record
to a number of votes at meetings of holders of Bionik US Shares equal to the number of Exchangeable Shares outstanding from time
to time (excluding Exchangeable Shares held by Bionik US and any subsidiary of Bionik US), which share is to be issued to and voted
by, the Trustee as described in the Voting and Exchange Trust Agreement.

 

    	- 2 -

    	 

    

 

“Business
Day” means any day other than a Saturday or Sunday or a day when banks in the City of Toronto are not generally open
for business.

 

“Closing”
means the completion of the Reverse Takeover and all of the transactions contemplated hereby.

 

“Closing
Date” means the date of the Closing, which shall be February 26, 2015 or such other date as the parties hereto may collectively
agree, acting reasonably, and in any event not later than February 27, 2015.

 

“misrepresentation”,
“material fact” and “material change” have the respective meanings ascribed thereto in the
Securities Act (Ontario).

 

“Material
Adverse Change” or “Material Adverse Effect” with respect to Bionik US or the Purchaser,
as the case may be, means any change (including a decision to implement such a change made by the board of directors or by senior
management who believe that confirmation of the decision by the board of directors is probable), event, occurrence, state of facts,
violation, inaccuracy, circumstance or effect that, individually or in the aggregate, is, or would reasonably be expected to be,
material and adverse to the business, assets (including intangible assets), liabilities (including any contingent liabilities that
may arise through outstanding, pending or threatened litigation or otherwise), obligations (whether absolute, accrued, conditional
or otherwise), capitalization, ownership, financial condition or results of operations of Bionik US or the Purchaser, as the case
may be, on a consolidated basis. 

 

“Material
Agreements” means collectively, the Registration Rights Agreement, the Support Agreement and the Voting and Exchange
Trust Agreement.

 

“Person”
shall be broadly interpreted and shall include any individual, corporation, partnership, joint venture, association, trust or other
legal entity.

 

“Registration
Rights Agreement” means the registration rights agreement dated February 26, 2015 among Bionik Canada and certain holders
of Exchangeable Shares, as the same will be novated to Bionik US on or subsequent to the date hereof.

 

“Support
Agreement” means the support agreement dated February 26, 2015 among Bionik Canada, Bionik US and Purchaser.

 

“Trustee”
means Computershare Trust Company of Canada and, subject to the provisions of the Voting and Exchange Trust Agreement, includes
any successor trustee.

 

“United
States” means the United States of America, its territories and possessions, any State of the United States and the District
of Columbia.

 

    	- 3 -

    	 

    

 

“Voting
and Exchange Trust Agreement” means the voting and exchange trust agreement dated February 26, 2015 among Bionik US,
Bionik Canada and Computershare Trust Company of Canada in connection with, among other things, the creation of a trust for the
benefit for the registered holders of the Exchangeable Shares (other than Bionik US or any subsidiary thereof).

 

		1.2	Interpretation Not Affected by Headings, etc.

 

The division of this Agreement
into articles, sections and subsections is for convenience of reference only and shall not affect the construction or interpretation
of this Agreement. The terms “this Agreement”, “hereof”, “herein”, and “hereunder”
and similar expressions refer to this Agreement and not to any particular article, section or other portion hereof and include
any Agreement or instrument supplementary or ancillary hereto.

 

		1.3	Number, etc.

 

Words importing the singular
number shall include the plural and vice versa, words importing the use of any gender shall include all genders and words importing
persons shall include firms and corporations and vice versa.

 

		1.4	Date for Any Action

 

In the event that any date on
which any action is required to be taken hereunder by any of the parties is not a Business Day such action shall be required to
be taken on the next succeeding day which is a Business Day.

 

		1.5	Currency

 

All sums of money which are referred
to in this Agreement are expressed in lawful money of the United States, unless otherwise indicated.

 

		1.6	Knowledge

 

Where any representation or warranty
contained in this Agreement is expressly qualified by reference to the knowledge of Bionik US or the Purchaser, as applicable,
it shall be deemed to refer to the actual knowledge after having made due inquiry of the officers of the particular company.

 

		1.7	Meanings

 

Unless otherwise specifically
indicated or the context otherwise requires “include”, “includes” and “including” shall be
deemed to be followed by the words “without limitation”.

 

    	- 4 -

    	 

    

 

Article 2

PURCHASED SHARE SUBSCRIPTION, LOAN AND

ISSUANCE OF PROMISSORY NOTE

 

		2.1	Subscription for Purchased Shares

 

At the Closing, Bionik Canada
shall issue and sell to the Purchaser on a private placement basis, and the Purchaser shall purchase from Bionik Canada, 100 Purchased
Shares at a price of $1.00 per Purchased Share for an aggregate purchase price of $100.00 (the “Subscription Proceeds”).

 

		2.2	Loan and Issuance of Promissory Note

 

At the Closing, the Purchaser
shall loan to Bionik Canada the sum of $0.00 in consideration of the issue by Bionik Canada to the Purchaser of the Promissory
Note.

 

		2.3	Closing

 

The Closing shall take place
at the offices of Bionik Canada’s legal counsel in Toronto, Ontario on the Closing Date.

 

		2.4	Closing Conditions and Deliveries

 

Upon the mutual satisfaction
of the conditions in this Section 2.4, at the Closing:

 

		(a)	the Purchaser shall pay the Subscription Proceeds for the Purchased Shares by delivery to Bionik
Canada of a certified cheque, bank draft or wire transfer of immediately available funds in the amount of the Subscription Proceeds;

 

		(b)	the Purchaser shall advance the loan by delivery to Bionik Canada of a certified cheque, bank draft
or wire transfer of immediately available funds;

 

		(c)	Bionik Canada shall issue and deliver to the Purchaser a certificate(s) registered to the Purchaser
representing the Purchased Shares;

 

		(d)	Bionik Canada shall issue and deliver to the Purchaser the Promissory Note;

 

		(e)	Bionik Canada shall deliver to the Purchaser a certificate of status (or equivalent) of Bionik
Canada dated no earlier than the Business Day immediately preceding the Closing Date;

 

		(f)	each of the Material Agreements shall have been duly executed and delivered by Bionik US and the
Purchaser, as applicable, and shall be legally valid and binding and enforceable against each of them, as applicable, in accordance
with their terms;

 

    	- 5 -

    	 

    

 

		(g)	the representations and warranties of Bionik US and the Purchaser contained in this Agreement and
the Material Agreements, as applicable, shall be true in all material respects on the Closing Date with the same effect as though
such representations and warranties had been made at and as of such time, other than in respect of representations and warranties
qualified by materiality which representations and warranties shall be true and correct in all respects;

 

		(h)	Bionik US and the Purchaser have performed, fulfilled or complied with, in all material respects,
all of their obligations, covenants and agreements contained in this Agreement and the Material Agreements, as applicable, to be
fulfilled or complied with by them at or prior to the Closing;

 

		(i)	the representations and warranties of Bionik Canada contained in this Agreement and the Material
Agreement, as applicable, shall be true in all material respects on the Closing Date with the same effect as though such representations
and warranties had been made at and as of such time, other than in respect of representations and warranties qualified by materiality
which representations and warranties shall be true and correct in all respects;

 

		(j)	Bionik Canada has performed, fulfilled or complied with, in all material respects, all of its obligations,
covenants and agreements contained in this Agreement and the Material Agreements, as applicable, to be fulfilled or complied with
by it at or prior to the Closing; and

 

		(k)	each of the Parties having properly completed, signed and delivered any further documentation as
required under applicable securities legislation or other regulatory authority.

 

Article 3

COVENANTS

 

		3.1	Covenants of Bionik US

 

		(a)	At or prior to the Closing, Bionik US shall have taken all necessary steps to create and issue
and shall issue to the Trustee the Bionik US Special Voting Share (and shall deliver the certificate representing such share to
the Trustee) to be hereafter held of record by the Trustee as trustee for and on behalf of, and for the use and benefit of, the
Beneficiaries and in accordance with the provisions of the Voting and Exchange Trust Agreement.

 

		(b)	Bionik US covenants that the registration statement or prospectus to be filed within 180 days of
the Closing covering some or all of the Bionik US Shares to be issued upon the redemption, retraction, exercise, exchange or conversion
of the Exchangeable Shares, and all information incorporated by reference therein shall constitutes full, true and plain disclosure
of all material facts relating to the Bionik US Shares and Bionik US, and will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. No
fact or information shall be omitted from such disclosure which shall be required to be stated in such disclosure or is necessary
to make the statement or information contained in such disclosure not misleading in light of the circumstances under which they
are to be made. Any such documents shall comply as at the date of such documents with all applicable securities laws, rules, regulations
and instruments.

 

    	- 6 -

    	 

    

 

		(c)	On or prior to the date hereof, (i) Bionik US, Brian Ray and John Lundgreen shall execute
and deliver or shall have executed and delivered the Spin-Off Agreement (the “Spin-Off Agreement”), pursuant
to which Bionik US shall assign all of the issued and outstanding capital stock of Strategic Dental Alliance Inc., a Colorado corporation
and a wholly-owned subsidiary of Bionik US (the “Spin-Off Subsidiary”), together with all of the business, operations,
assets, and goodwill of the Spin-Off Subsidiary (other than cash and cash equivalents) and certain liabilities, in exchange for
an indemnity from Brian Ray and John Lundgreen against claims by any Persons arising in connection with such business, operation,
employment matters, warranties or otherwise (the “Spin-Off”) and (ii) Bionik US and Tungsten 74 LLC shall
execute and deliver or shall have executed and delivered the Assignment and Assumption Agreement pursuant to which Tungsten 74
LLC assumed all remaining liabilities of Bionik US through the date hereof (the “Assignment”).

 

		(d)	Prior to the Closing, Bionik US shall (i) loan $0.00, representing a portion of the net proceeds
from the Unit Offering, to the Purchaser in exchange for a non-interest bearing promissory note of the Purchaser in an equivalent
principal amount (the “Bionik US Loan”), and (ii) subscribe for common stock of the Purchaser using the balance
of the net proceeds from the Unit Offering in an amount equal to the Subscription Proceeds. At or prior to the Closing, Bionik
US shall cause the Purchaser to (i) provide a loan to Bionik Canada in an amount equal to the Bionik US Loan in exchange for the
Promissory Note, and (ii) subscribe for the Purchased Shares at a price of $1.00 per Purchased Share for a total subscription price
of $100.00.

 

		3.2	Covenants of Bionik Canada

 

		(a)	On or prior to one (1) Business Day before the Closing Date, Bionik Canada shall have filed the
Articles of Amendment with Industry Canada.

 

Article 4

REPRESENTATIONS AND WARRANTIES

 

		4.1	Representations and Warranties of Bionik US and Purchaser

 

Bionik US and Purchaser, jointly
and severally, represent and warrant to and in favour of Bionik Canada as follows, and acknowledge that Bionik Canada is relying
upon such representations and warranties in connection with the completion of the transactions contemplated herein:

 

		(a)	The Purchaser and Bionik US are aware that an investment in Bionik Canada involves a significant
degree of risk, involving a number of very significant risks and has carefully read and considered the matters set forth in the
Memorandum.

 

    	- 7 -

    	 

    

 

		(b)	None of the Purchased Shares are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or any state securities laws. The Purchaser understands that the offering and sale of the Purchased Shares are
intended to be exempt from registration under the Securities Act, by virtue of Section 4(a)(2) thereof and/or the provisions of
Regulation D promulgated thereunder, based, in part, upon the representations, warranties and agreements of the Purchaser contained
in this Agreement.

 

		(c)	Prior to the execution of this Agreement, the Purchaser and Bionik US, and their respective attorneys,
accountants, purchaser representatives and/or tax advisers, if any (collectively, the “Advisers”), have received
the Memorandum and all other documents requested by the Purchaser and Bionik US, have carefully reviewed them and understand the
information contained therein.

 

		(d)	Neither the Securities and Exchange Commission nor any state or provincial securities commission
or other regulatory authority has approved the Purchased Shares, or passed upon or endorsed the merits of the offering of the Purchased
Shares, or confirmed the accuracy or determined the adequacy of the Memorandum. The Memorandum has not been reviewed by any federal,
state or other regulatory authority.

 

		(e)	All documents, records, and books pertaining to the investment in the Purchased Shares have been
made available for inspection by the Purchaser, Bionik US and their respective Advisers, if any.

 

		(f)	The Purchaser, Bionik US and their respective Advisers, if any, have had a reasonable opportunity
to ask questions of and receive answers from a person or persons acting on behalf of Bionik Canada concerning the Purchased Shares,
the business and financial condition of Bionik Canada, and all such questions have been answered to the full satisfaction of the
Purchaser and their respective Advisers, if any.

 

		(g)	The Purchaser and Bionik US are each unaware of, are in no way relying on, and did not become aware
of the offering of the Purchased Shares through or as a result of, any form of general solicitation or general advertising including,
without limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar media
or broadcast over television, radio or the Internet (including, without limitation, internet “blogs,” bulletin boards,
discussion groups and social networking sites) in connection with the offering and sale of the Purchased Shares and are not subscribing
for the Purchased Shares and did not become aware of the offering of the Purchased Shares through or as a result of any seminar
or meeting to which the Purchaser or Bionik US were invited by, or any solicitation of a subscription by, a person not previously
known to the Purchaser in connection with investments in securities generally.

 

		(h)	Neither the Purchaser nor Bionik US is relying on Bionik Canada or any of its employees, agents,
lawyers or advisers with respect to the legal, tax, economic and related considerations of an investment in the Purchased Shares,
and the Purchaser and Bionik US have each relied on the advice of, or have consulted with, only their own advisers.

 

    	- 8 -

    	 

    

 

		(i)	The Purchaser and Bionik US, directly and indirectly, as the case may be, are acquiring the Purchased
Shares solely for their own account for investment purposes only and not with a view to or intent of resale or distribution thereof,
in whole or in part. The Purchaser and Bionik US have no agreement or arrangement, formal or informal, with any person to sell
or transfer all or any part of the Purchased Shares, directly and indirectly, as the case may be, and the Purchaser and Bionik
US have no plans to enter into any such agreement or arrangement.

 

		(j)	The Purchaser and indirectly Bionik US must bear the substantial economic risks of the investment
in the Purchased Shares indefinitely because none of them may be sold, hypothecated or otherwise disposed of unless subsequently
registered under the Securities Act and applicable state securities laws or an exemption from such registration is available.

 

		(k)	The Purchaser is duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization, the consummation of the transactions contemplated hereby and the entering into of this Agreement and the Material
Agreements, as applicable, is authorized by, and will not result in a violation of law or its charter, by-laws or other organizational
documents, such entity has full power and authority to execute and deliver this Agreement and the Material Agreements and all other
related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the securities constituting
the Purchased Shares, the execution and delivery of this Agreement and the Material Agreements have been duly authorized by all
necessary action, this Agreement and the Material Agreements have been duly executed and delivered on behalf of such entity and
are legal, valid and binding obligations of such entity. The execution and delivery of this Agreement and the Material Agreements
will not violate, conflict or result in a breach of any term of any order, judgment, injunction, agreement or controlling document
to which the Purchaser is a party or by which it is bound.

 

		(l)	Bionik US and the Purchaser are not insolvent and are able to meet all of their financial liabilities
as they become due and no winding-up, liquidation, dissolution or bankruptcy proceedings have been commenced or are being commenced
or contemplated by Bionik US or the Purchaser, and other than the Reverse Take Over, no merger, consolidation, amalgamation, sale
of all or substantially all of the assets or sale of their respective businesses have been commenced or are being commenced or
contemplated by Bionik US or the Purchaser and Bionik US has no knowledge of any such proceedings or transactions having been commenced
or being contemplated in respect of Bionik US or the Purchaser by any other party;

 

    	- 9 -

    	 

    

 

		(m)	Bionik US and the Purchaser have been conducting their respective businesses and operations and
are conducting the Reverse Takeover and Unit Offering in compliance in all material respects with all applicable laws and regulations
of each jurisdiction in which they carry on such businesses or operations, and, to the knowledge of Bionik US, there are no facts
that would give rise to a notice of material non-compliance with any such laws and regulations.

 

		(n)	The Purchaser and Bionik US are each satisfied that they have received adequate information with
respect to all matters which they or their advisers, if any, consider material to the Purchaser’s and Bionik US’s,
as the case may be, decision to make this investment.

 

		(o)	The Purchaser and Bionik US each acknowledge that any estimates or forward-looking statements or
projections included in the Memorandum were prepared by Bionik Canada in good faith but that the attainment of any such projections,
estimates or forward-looking statements cannot be guaranteed by Bionik Canada and should not be relied upon.

 

		(p)	The Bionik US Shares have been registered under Section 12(g) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) and Bionik US is subject to the periodic reporting requirements of Section
13 of the Exchange Act. Bionik US has made available to Bionik Canada true, complete, and correct copies of all forms, reports,
schedules, statements, and other documents required to be filed by it under the Exchange Act, as such documents have been amended
since the time of the filing thereof (collectively, including all forms, reports, schedules, statements, exhibits, and other documents
filed by Bionik US therewith, the “SEC Documents”). The SEC Documents, including, without limitation, any financial
statements and schedules included therein, at the time filed or, if subsequently amended, as so amended, (i) did not contain any
untrue statement of a material fact required to be stated therein or necessary in order to make the statements therein not misleading
and (ii) complied in all material respects with the applicable requirements of the Exchange Act and the applicable rules and regulations
thereunder.

 

		(q)	Except as otherwise disclosed in the SEC Documents, Bionik US maintains disclosure controls and
procedures required by Rule 13a-15 or 15d-15 under the Exchange Act; such controls and procedures are effective to ensure that:

 

		(i)	all material information concerning Bionik US is made known on a timely basis to the individuals
responsible for the preparation of Bionik US’s filings with the SEC and other public disclosure documents;

 

		(ii)	transactions are executed in accordance with management’s general or specific authorizations;

 

		(iii)	transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles in the United States and to maintain asset accountability;

    	- 10 -

    	 

    

 

		(iv)	access to assets is permitted only in accordance with management’s general or specific authorization;
and

 

		(v)	the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences.

 

Bionik US has made available to
Bionik Canada copies of, all written descriptions of, and all policies, manuals and other documents promulgating, such disclosure
controls and procedures, if any. The books, records and accounts of Bionik US accurately and fairly reflect, in reasonable detail,
the transactions in, and dispositions of, the assets of, and the results of operations of, Bionik US all to the extent required
by generally accepted accounting principles in the United States.

 

		(r)	The information and statements in the Memorandum (except information and statements relating solely
to Bionik Canada and furnished in writing by Bionik Canada for use therein (“Bionik Canada’s Information”)
and statistical, market related data and/or other information that is identified in the Memorandum as being from a third party
(the “Third Party Information”)) are true and correct in all material respects and contain no misrepresentation
and the Memorandum does not contain any untrue statement of a material fact or omit to state a material fact (except with respect
to Bionik Canada’s Information and the Third Party Information) necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading and the Memorandum complies with all applicable securities
laws.

 

		(s)	The Chief Executive Officer and the Chief Financial Officer of Bionik US has signed, and Bionik
US has filed with or furnished to the Securities and Exchange Commission (the “SEC”), as the case may be, all
certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002; such certifications contain no qualifications
or exceptions to the matters certified therein and have not been modified or withdrawn; and neither Bionik US nor any of its officers
has received notice from any governmental entity questioning or challenging the accuracy, completeness, form or manner of filing
or submission of such certifications.

 

		(t)	Bionik US has heretofore made available to Bionik Canada complete and correct copies of all certifications
filed with or furnished to the SEC, as the case may be, pursuant to Sections 302 and 906 of Sarbanes-Oxley Act of 2002 and hereby
reaffirms, represents and warrants to Bionik Canada the matters and statements made in such certificates.

 

		(u)	At the date hereof:

 

		(i)	each of the Bionik US Shares is eligible to trade and be quoted on, and is quoted on, the over-the-counter
Bulletin Board market, and/or the OTCQB market and/or OTCQX market and/or the OTCPink market (the “OTCBB”) and
has received no notice or other communication indicating that such eligibility is subject to challenge or review by the any applicable
regulatory agency, electronic market administrator, or exchange;

    	- 11 -

    	 

    

 

		(ii)	Bionik US has and shall have performed or satisfied all of its undertakings to, and of its obligations
and requirements with, the SEC;

 

		(iii)	Bionik US has not, and shall not have taken any action that would preclude, or otherwise jeopardize,
the inclusion of the Bionik US Shares for quotation on the OTCBB; and

 

		(iv)	the Bionik US Shares are eligible for participation in The Depository Trust Company book entry
system.

 

		(v)	Except for the Purchaser, taking into account the Spin-Off, Bionik US has no subsidiaries
or affiliated corporation or owns any interest in any other enterprise (whether or not such enterprise is a corporation). Bionik
US has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware with
full power and authority (corporate and other) to own, lease and operate its properties and conduct its business as described in
the SEC Documents. Bionik US is duly qualified to do business as a foreign corporation in each jurisdiction, if any,
for which its activities would require it to be so qualified, and is in good standing in each jurisdiction in which the ownership
or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified
or be in good standing would not have a Material Adverse Effect; no proceeding has been instituted in any such jurisdiction, revoking,
limiting or curtailing, or seeking to revoke, limit or curtail, such power and authority or qualification; Bionik US is in possession
of, and operating in compliance with, all authorizations, licenses, certificates, consents, orders and permits from state, federal,
foreign and other regulatory authorities that are material to the conduct of its business, all of which are valid and in full force
and effect; Bionik US is not in violation of its charter or bylaws or in default in the performance or observance of any obligation,
agreement, covenant or condition contained in any material bond, debenture, note or other evidence of indebtedness, or in any material
lease, contract, indenture, mortgage, deed of trust, loan agreement, joint venture or other agreement or instrument to which it
is a party or by which it or its properties or assets may be bound, which violation or default would have a Material Adverse Effect;
and Bionik US is not in violation of any law, order, rule, regulation, writ, injunction, judgment or decree of any court, government
or governmental agency or body, domestic or foreign, having jurisdiction over Bionik US or over its properties or assets, which
violation would have a Material Adverse Effect. The SEC Documents, as of the dates thereof, accurately describe any corporation,
association or other entity owned or controlled, directly or indirectly, by Bionik US. The Purchaser has no assets or liabilities
as of the date hereof, was formed for the sole purpose of acquiring the Purchased Shares on behalf of Bionik US and is wholly-owned
by Bionik US.

 

    	- 12 -

    	 

    

 

		(w)	Bionik US has all requisite power and authority to execute, deliver, and perform this Agreement
and the Material Agreements, as applicable. All necessary proceedings of Bionik US have been duly taken to authorize the execution,
delivery, and performance of this Agreement and the Material Agreements. This Agreement and the Material Agreements, as applicable,
have been duly authorized, executed, and delivered by Bionik US, constitute the legal, valid, and binding obligation of Bionik
US, and are enforceable as to Bionik US in accordance with their terms. Except as otherwise set forth in this Agreement and the
Material Agreements, as applicable, no consent, authorization, approval, order, license, certificate, or permit of or from, or
declaration or filing with, any federal, state, local, or other governmental authority or any court or other tribunal is required
by Bionik US for the execution, delivery, or performance of this Agreement and the Material Agreements. No consent, approval, authorization
or order of, or qualification with, any court, government or governmental agency or body, domestic or foreign, having jurisdiction
over Bionik US or over its properties or assets is required for the execution and delivery of this Agreement and the Material Agreements
by Bionik US and the consummation by Bionik US of the transactions herein and therein contemplated, except such as may be required
under the Securities Act or under state or other securities or blue sky laws, all of which requirements have been, or in accordance
therewith will be, satisfied in all material respects. No consent of any party to any material contract, agreement, instrument,
lease, license, arrangement, or understanding to which Bionik US is a party, or to which its or any of its businesses, properties,
or assets are subject, is required for the execution, delivery, or performance of this Agreement and the Material Agreements, as
applicable, by Bionik US; and the execution, delivery, and performance of this Agreement and the Material Agreements, as applicable,
by Bionik US will not violate, result in a breach of, conflict with, or (with or without the giving of notice or the passage of
time or both) entitle any party to terminate or call a default under, entitle any party to receive rights or privileges that such
party was not entitled to receive immediately before this Agreement and the Material Agreements were executed under, or create
any obligation on the part of Bionik US to which it was not subject immediately before this Agreement and the Material Agreements
were executed under, any term of any such material contract, agreement, instrument, lease, license, arrangement, or understanding,
or violate or result in a breach of any term of the certificate of incorporation or by-laws of Bionik US or (if the provisions
of this Agreement and the Material Agreements are satisfied) violate, result in a breach of, or conflict with any law, rule, regulation,
order, judgment, decree, injunction, or writ of any court, government or governmental agency or body, domestic or foreign, having
jurisdiction over Bionik US or over its properties or assets.

 

    	- 13 -

    	 

    

 

		(x)	There is not any pending or, to the best of Bionik US’s knowledge, threatened, action, suit,
claim or proceeding against Bionik US or the Purchaser, or any of Bionik US’s or the Purchaser’s current or past officers
or directors or any of the respective properties, assets or rights of Bionik US or the Purchaser, before any court, government
or governmental agency or body, domestic or foreign, having jurisdiction over Bionik US or the Purchaser or over Bionik US’s
or the Purchaser’s current or past officers or directors or the properties of Bionik US or the Purchaser, or otherwise that
(i) is reasonably likely to result in any Material Adverse Change, (ii) might prevent consummation of the transactions contemplated
by this Agreement, or (iii) alleging violation of any Federal, provincial or state securities laws.

 

		(y)	The authorized and issued and outstanding capital stock of Bionik US and the Purchaser is as set
forth in the SEC Documents. Each of such outstanding shares of Bionik US Shares and shares of Purchaser is duly and validly authorized,
validly issued, fully paid, and nonassessable, has not been issued and is not owned or held in violation of any pre-emptive or
similar right of stockholders. Except as disclosed in the SEC Documents, (i) there is no commitment, plan, or arrangement to issue,
and no outstanding option, warrant, or other right calling for the issuance of, any share of capital stock of, or any security
or other instrument convertible into, exercisable for, or exchangeable for capital stock of, Bionik US or the Purchaser, and (ii)
except as described in the SEC Documents, there is outstanding no security or other instrument convertible into or exchangeable
for capital stock of Bionik US or the Purchaser. Other than as described in the SEC Documents, Bionik US and the Purchaser have
no stock option, stock bonus and other stock plans or arrangements.

 

		(z)	All necessary corporate action has been taken to validly authorize and issue the Bionik US Special
Voting Share as fully paid and non-assessable and with of all of the attributes as set out in the Certificate of Designation in
Schedule “A” attached hereto, at or prior to the Closing.

 

		(aa)	Until the expiry of the rights to redeem, retract, exercise, exchange or convert the Exchangeable
Shares pursuant to their terms, there shall be at all times set aside, reserved, authorized and kept available for issuance that
number of authorized but unissued Bionik US Shares as shall, from time to time, be sufficient to permit the redemption, retraction,
exercise, exchange or conversion, in accordance with the terms of the Exchangeable Shares, of the rights to redeem, retract, exercise,
exchange or convert into Bionik US Shares attaching to all of the Exchangeable Shares then outstanding based on the number of Bionik
US Shares issuable on the redemption, retraction, exercise, exchange or conversion of the Exchangeable Shares (including, without
limitation, any adjustments required as a result of the terms of Exchangeable Shares).

 

		(bb)	The Bionik US Shares so set aside and reserved are hereby allotted to holders of the Exchangeable
Shares who exercise the rights to redeem, retract, exercise, exchange or convert into Bionik US Shares attaching to the Exchangeable
Shares in accordance with the terms thereof and, upon redemption, retraction, exercise, exchange or conversion of the Exchangeable
Shares in accordance with the terms thereof, the Bionik US Shares to which the holders of the Exchangeable Shares are entitled
shall be issued as fully paid and non-assessable.

 

    	- 14 -

    	 

    

 

		(cc)	All necessary corporate action has been taken to authorize the issue and sale of, and the delivery
of certificates representing, up to 16,000,000 Bionik US Shares and up to 16,000,000 Bionik US warrants to purchase up to 16,000,000
Bionik US Shares in the aggregate and, upon the issue thereof, the Bionik US Shares will be validly issued as fully paid and non-assessable
shares, the warrants to purchase Bionik US Shares will be validly issued and, upon payment of the requisite consideration therefor,
the underlying Bionik US Shares will be validly issued as fully paid and non-assessable shares.

 

		(dd)	The Unit Offering shall result in net proceeds of a minimum of $6,000,000.

 

		(ee)	The Purchaser is purchasing sufficient Purchased Shares so that the aggregate acquisition cost
of the Purchased Shares payable in cash at the Closing is not less than $150,000 and the Purchaser is not a corporation, syndicate,
partnership or other form of incorporated or non-incorporated entity or organization created solely to permit the purchase of the
Purchased Shares without a prospectus by a group of individuals whose individual share of the aggregate acquisition cost of the
Purchased Shares is less than $150,000.

 

		(ff)	The Purchaser is purchasing the Promissory Note for such principal amount so that the aggregate
acquisition cost of the Promissory Note payable in cash at the Closing is not less than $150,000 and the Purchaser is not a corporation,
syndicate, partnership or other form of incorporated or non-incorporated entity or organization created solely to permit the purchase
of the Promissory Note without a prospectus by a group of individuals whose individual share of the aggregate acquisition cost
of the Promissory Note is less than $150,000.

 

		(gg)	Cutler & Co., LLC, certified public accountants, examined the financial statements of Bionik
US, together with the related schedules and notes, as of December 31, 2013 and for the year then ended, and Ronald R. Chadwick,
P.C., certified public accountant, examined the financial statements of Bionik US, together with the related schedules and notes,
for the period from January 8, 2010 (inception) through December 31, 2012, and for the years ended December 31, 2010, 2011 and
2012, filed with the SEC as a part of the SEC Documents, are independent accountants within the meaning of the Securities Act,
the Exchange Act, and the rules and regulations promulgated thereunder; and the audited financial statements of Bionik US, together
with the related schedules and notes, and the unaudited financial information, forming part of the SEC Documents, fairly present
and will fairly present the financial position and the results of operations of Bionik US at the respective dates and for the respective
periods to which they apply; and all audited financial statements of Bionik US, together with the related schedules and notes,
and the unaudited financial information, filed with the SEC as part of the SEC Documents, complied and will comply as to form in
all material respects with applicable accounting requirements and with the rules and regulations of the SEC with respect hereto
when filed, have been and will be prepared in accordance with generally accepted accounting principles in the United States consistently
applied throughout the periods involved except as may be otherwise stated therein (except as may be indicated in the notes thereto
or as permitted by the rules and regulations of the SEC) and fairly present and will fairly present, subject in the case of the
unaudited financial statements, to customary year end audit adjustments, the financial position of Bionik US as at the dates thereof
and the results of its operations and cash flows. The procedures pursuant to which the aforementioned financial statements have
been audited are compliant with generally accepted auditing standards in the United States. The selected and summary financial
and statistical data included in the SEC Documents present and will present fairly the information shown therein and have been
compiled on a basis consistent with the audited financial statements presented therein. No other financial statements or schedules
are required to be included in the SEC Documents. The financial statements referred to in this section contain all certifications
and statements required under the SEC’s Order, dated June 27, 2002, pursuant to Section 21(a)(1) of the Exchange Act (File
No. 4-460), Rule 13a-14 or 15d-14 under the Exchange Act, or 18 U.S.C. Section 1350 (Sections 302 and 906 of the Sarbanes-Oxley
Act of 2002) with respect to the report relating thereto. Since September 30, 2014 (the “Last Bionik US Financial Statement
Date”):

 

    	- 15 -

    	 

    

 

		(i)	There has at no time been a Material Adverse Change.

 

		(ii)	Bionik US has not authorized, declared, paid, or effected any dividend or liquidating or other
distribution in respect of its capital stock or any direct or indirect redemption, purchase, or other acquisition of any stock
of Bionik US.

 

		(iii)	Except as set forth in the SEC Documents, the operations and businesses of Bionik US have been
conducted in all respects only in the ordinary course.

 

Other than a “going concern”
qualification in the report of the auditors with respect to the financial statements of Bionik US, there is no fact known to Bionik
US which materially adversely affects or in the future (as far as Bionik US can reasonably foresee) may materially adversely affect
the financial condition, results of operations, businesses, properties, assets, liabilities, or future prospects of Bionik US;
provided, however, that Bionik US does not express any opinion as to political or economic matters of general applicability. Bionik
US has made known, or caused to be made known, to the accountants or auditors who have prepared, reviewed, or audited the aforementioned
consolidated financial statements all material facts and circumstances which could affect the preparation, presentation, accuracy,
or completeness thereof.

 

		(hh)	Subsequent to the respective dates as of which information is given in the SEC Documents, there
has not been (i) any Material Adverse Change, (ii) any transaction committed to or consummated that is material to Bionik US, (iii)
any obligation, direct or contingent, that is material to Bionik US incurred by Bionik US, except such obligations as have been
incurred in the ordinary course of business, (iv) any change in the capital stock or outstanding indebtedness of Bionik US or any
subsidiary thereof that is material to Bionik US, (v) any dividend or distribution of any kind declared, paid, or made on the capital
stock of Bionik US, or (vi) any loss or damage (whether or not insured) to the property of Bionik US which has a Material Adverse
Effect.

 

    	- 16 -

    	 

    

 

		(ii)	As of the date hereof and giving effect to the Spin-Off and the Assignment, (A) other than
the shares of the Purchaser, neither Bionik US nor the Purchaser shall have any, business operations, direct or indirect, properties
or assets and Bionik US and the Purchaser shall be free and clear of any pledge, lien, security interest, encumbrance, claim or
equitable interest and (B) neither Bionik US nor the Purchaser shall be party to any agreements except for this Agreement, the
Material Agreements, the assignment and assumption with respect to the Assignment and the Spin-Off Agreement and each shall have
been duly authorized, executed and delivered by Bionik US and the Purchaser, as applicable, and each shall be a legal, valid and
binding agreement, enforceable against the parties thereto in accordance with their terms.

 

		(jj)	At the Closing and giving effect to the Spin-Off and the Assignment, neither Bionik US nor the
Purchaser shall have any liability of any nature, accrued or contingent, direct or indirect, including, without limitation, liabilities
for federal, state, local, or foreign taxes and penalties, interest, and additions to tax (“Taxes”), and liabilities
to customers, suppliers or finders. Without limiting the generality of the foregoing, the amounts set up as provisions for Taxes,
if any, in the financial statements of Bionik US at the Last Bionik US Financial Statement Date (the “Last Bionik US Financial
Statements”) are sufficient for all accrued and unpaid Taxes of Bionik US, whether or not due and payable and whether
or not disputed, under tax laws, as in effect on the Last Bionik US Financial Statement Date or now in effect, for the period ended
on such date and for all fiscal periods prior thereto. The execution, delivery, and performance of this Agreement and the Material
Agreements, as applicable, by Bionik US and the Purchaser will not cause any Taxes to be payable or cause any lien, charge, or
encumbrance to secure any Taxes to be created either immediately or upon the non-payment of any Taxes. Bionik US and the Purchaser
have filed all federal, state, local, and foreign tax returns required to be filed by them; have made available to Bionik Canada
a true and correct copy of each such return which was filed; have paid (or have established on the last balance sheet included
in the Last Bionik US Financial Statements a reserve for) all Taxes, assessments, and other governmental charges payable or remittable
by them or levied upon them or their properties, assets, income, or franchises which are due and payable; and neither Bionik US
nor the Purchaser have received any report as to adjustments from any taxing authority since inception or a statement as to any
litigation, governmental or other proceeding (formal or informal), or investigation pending, threatened, or in prospect with respect
to any such report or the subject matter of such report. Bionik US and the Purchaser have paid all taxes payable thereby due on
or prior to the date hereof.

 

    	- 17 -

    	 

    

 

		(kk)	Except as disclosed in the SEC Documents, Bionik US and the Purchaser do not have any insurance;
Bionik US and the Purchaser have at no time been refused any insurance coverage sought or applied for.

 

		(ll)	(i) 	Bionik US and the Purchaser each have no employees.

 

		(ii)	Bionik US and the Purchaser each do not have, or contribute to, and have never maintained or contributed
to, any pension, profit-sharing, option, other incentive plan, or any other type of Employee Benefit Plan (as defined in Section
3(3) of ERISA) or Pension Plan (as defined in ERISA) and Bionik US and the Purchaser each do not have any obligation to or customary
arrangement with employees for bonuses, incentive compensation, vacations, severance pay, sick pay, sick leave, insurance, service
award, relocation, disability, tuition refund, or other benefits, whether oral or written.

 

		(mm)	Bionik US and the Purchaser have no, and have no rights to use, patents, patent rights, inventions,
trade secrets, know-how, trademarks, service marks, trade names, logos, or copyrights. Bionik US and the Purchaser have not received
any notice of, or have knowledge of, any infringement of or conflict with asserted rights of Bionik US or the Purchaser by others
with respect to any patents, patent rights, inventions, trade secrets, know-how, trademarks, service marks, trade names, logos,
or copyrights; and Bionik US and the Purchaser have not received any notice of, or have no knowledge of, any infringement of, or
conflict with, asserted rights of others with respect to any patents, patent rights, inventions, trade secrets, know-how, trademarks,
service marks, trade names, logos, or copyrights described or referred to in the SEC Documents as owned by or used by them.

 

		(nn)	Bionik US has been advised concerning the Investment Company Act of 1940, as amended (the “Investment
Company Act”), and the rules and regulations thereunder, and has in the past conducted their affairs in such a manner
as to ensure that it is not and will not become an “investment company” or a company “controlled” by an
“investment company” within the meaning of the Investment Company Act and such rules and regulations.

 

		(oo)	(i) 	Bionik US and the Purchaser have not, and no person or entity acting on behalf or at the request of Bionik US or the Purchaser
has, at any time since their inception (i) made any unlawful contribution to any candidate for foreign office or failed to disclose
fully any contribution in violation of law, or (ii) made any payment to any federal or state governmental officer or official,
or other person charged with similar public or quasi-public duties, other than payments required or permitted by the laws of the
United States or any other applicable jurisdiction.

 

    	- 18 -

    	 

    

 

		(ii)	To the best knowledge of Bionik US, no director, officer, agent, employee, or other person associated
with, or acting on behalf of, Bionik US and the Purchaser, has, directly or indirectly: used any corporate funds for unlawful contributions,
gifts, entertainment, or other unlawful expenses relating to political activity; made any unlawful payment to foreign or domestic
government officials or employees or to foreign or domestic political parties or campaigns from corporate funds; violated any provision
of the Foreign Corrupt Practices Act of 1977, as amended; or made any bribe, rebate, payoff, influence payment, kickback, or other
unlawful payment. Bionik US’ and the Purchaser’s internal accounting controls and procedures are sufficient to cause
Bionik US and the Purchaser to each comply in all respects with the Foreign Corrupt Practices Act of 1977, as amended.

 

		(iii)	Neither Bionik US nor the Purchaser, nor any officer, director or affiliate of Bionik US or the
Purchaser, has been, within the five years ending on the Closing Date, a party to any bankruptcy petition against such person or
against any business of which such person was affiliated; convicted in a criminal proceeding or subject to a pending criminal proceeding
(excluding traffic violations and other minor offenses); subject to any order, judgment or decree, not subsequently reversed, suspended
or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting
their involvement in any type of business, securities or banking activities; or found by a court of competent jurisdiction in a
civil action, by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities
law, and the judgment has not been reversed, suspended or vacated.

 

		(pp)	Neither Bionik US nor the Purchaser have, and no person acting on behalf thereof, has taken or
will take, directly or indirectly, any action designed to, or that might reasonably be expected to cause or result in, stabilization
in violation of law, or manipulation, of the price of Bionik US Shares.

 

		(qq)	Neither Bionik US nor, to the knowledge of Bionik US, any other party thereto is in material default
or breach of any contract or agreement of Bionik US and there exists no condition, event or act which, with the giving of notice
or lapse of time or both, would constitute a material default or breach under any contract or agreement of Bionik US to which would
give rise to a right of termination on the part of any other party to such agreement or contract.

 

		(rr)	Neither the Purchaser nor, to the knowledge of Bionik US, any other party thereto is in material
default or breach of any contract or agreement of the Purchaser and there exists no condition, event or act which, with the giving
of notice or lapse of time or both, would constitute a material default or breach under any contract or agreement of the Purchaser
to which would give rise to a right of termination on the part of any other party to such agreement or contract.

 

    	- 19 -

    	 

    

 

		(ss)	Except as set forth in the SEC Documents, (i) Bionik US and the Purchaser are in compliance in
all material respects with all rules, laws and regulations relating to the use, treatment, storage and disposal of toxic substances
and protection of health or the environment (“Environmental Laws”) that are applicable to their business, (ii)
Bionik US and the Purchaser have not received notice from any governmental authority or third party of an asserted claim under
Environmental Laws, (iii) to the best knowledge of Bionik US, Bionik US and the Purchaser are not likely to be required to make
future material capital expenditures to comply with Environmental Laws (iv) no property which is owned, leased or occupied by Bionik
US or the Purchaser has been designated as a Superfund site pursuant to the Comprehensive Response, Compensation, and Liability
Act of 1980, as amended (42 U.S.C. § 9601, et seq.), or otherwise designated as a contaminated site under applicable state
or local law, and (v) Bionik US and the Purchaser are not in violation of any federal or state law or regulation relating to occupational
safety or health.

 

		(tt)	As of the date hereof, there are no outstanding loans, advances or guarantees of indebtedness by
Bionik US or the Purchaser to, or for the benefit of, any of the officers, directors, or director-nominees of Bionik US and the
Purchaser or any of the members of the families of any of them. Any of such loans, advances or guarantees of indebtedness that
may be disclosed in the SEC Documents are terminated or assigned in full pursuant to the Spin-Off and the Assignment as of the
date hereof.

 

		(uu)	No stockholder of Bionik US has any right to request or require Bionik US to register the sale
of any shares owned by such stockholder under the Securities Act on any registration statement, except pursuant to the terms of
the Unit Offering and the Registration Rights Agreement.

 

		(vv)	Bionik US and the Purchaser are not a party to a shareholders’ agreement nor to the knowledge
of Bionik US, is there any shareholders’ agreement or other contract, which in any manner affects the voting control of any
of the securities of Bionik US or the Purchaser.

 

		(ww)	Bionik US and the Purchaser are each in compliance with, and are not in violation of, applicable
federal, state, local or foreign statutes, laws and regulations (including without limitation, any applicable building, zoning
or other law, ordinance or regulation) affecting their properties or the operation of their business, including, without limitation,
Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated pursuant thereto or thereunder. Bionik US and the Purchaser
are each not subject to any order, decree, judgment or other sanction of any court, administrative agency or other tribunal.

 

		(xx)	As of the date hereof, Bionik US and the Purchaser are not party to any contract, agreement or
arrangement other than this Agreement, the Material Agreements, the assignment and assumption with respect to the Assignment, the
Spin-Off Agreement as applicable. Any such other contract, agreement or arrangement that may be disclosed in the SEC Documents
are terminated or assigned in full pursuant to the Spin-Off as of the date hereof.

 

    	- 20 -

    	 

    

 

		(yy)	No representation or warranty by Bionik US or the Purchaser in this Agreement and the Material
Agreements, as applicable, or any document furnished or to be furnished by Bionik US or the Purchaser to Bionik Canada in accordance
with this Agreement and the Material Agreements, as applicable, contains any untrue statement of a material fact, or omits to state
a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.

 

		(zz)	There is no Person acting at the request or on behalf of Bionik US or the Purchaser that is entitled
to any brokerage or finder’s fee or other compensation in connection with the transactions contemplated by this Agreement
and the Material Agreements.

 

		4.2	Representations and Warranties of Bionik Canada

 

Bionik Canada represents and
warrants to and in favour of Bionik US and Purchaser as follows, and acknowledges that Bionik US and Purchaser are relying upon
such representations and warranties in connection with the completion of the transactions contemplated herein:

 

		(a)	Bionik Canada is a corporation duly incorporated, validly existing and in good standing under the
laws of the jurisdiction of its incorporation and has the requisite corporate power to own its properties and to carry on its business
as presently conducted.

 

		(b)	This Agreement and any other agreements, documents or instruments delivered or required to be delivered
together with or pursuant to this Agreement or in connection herewith (collectively “Transaction Documents”)
have been duly authorized, executed and delivered by Bionik Canada and are valid and binding agreements of Bionik Canada enforceable
in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar
laws of general applicability relating to or affecting creditors’ rights generally and to general principles of equity. Bionik
Canada has full corporate power and authority necessary to enter into and deliver the Transaction Documents and to perform its
obligations thereunder.

 

		(c)	The information in the Memorandum as it relates to Bionik Canada, including, without limitation,
any financial statements of Bionik Canada and schedules included therein, as of the date thereof or, if subsequently amended and/or
supplemented, as so amended and/or supplemented did not contain any untrue statement of a material fact or omit to state a material
fact required or necessary to be stated therein in order to make the statements contained therein with respect to Bionik Canada
not misleading.

 

    	- 21 -

    	 

    

 

Article 5

RESALE RESTRICTIONS

 

		5.1	Acknowledgement

 

The Purchaser understands and
acknowledges that the Purchased Shares will be subject to resale restrictions, the terms of which may be endorsed on the certificates
representing the Purchased Shares as a printed legend.

 

		5.2	Legend

 

The Purchaser understands and
acknowledges that upon the original issuance thereof, and until such time as the same is no longer required under applicable requirements
of applicable securities legislation, the certificate representing the Purchased Shares: will bear the following legends in addition
to any other legends that may be required to be endorsed thereon:

 

“UNLESS PERMITTED UNDER SECURITIES
LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS FOUR MONTHS AND A DAY AFTER THE LATER
OF (I) [INSERT DISTRIBUTION DATE], AND (II) THE DATE THE ISSUER BECAME A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY.

 

THE SECURITIES OFFERED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND ARE BEING OFFERED AND SOLD IN
RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS
ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO
REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION,
ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED
THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM OR THIS SUBSCRIPTION AGREEMENT. ANY REPRESENTATION TO
THE CONTRARY IS UNLAWFUL.”

 

    	- 22 -

    	 

    

 

Article 6

USE OF PERSONAL INFORMATION

 

		6.1	Acknowledgment

 

The Purchaser acknowledges and
consents to the fact Bionik Canada may be required by applicable securities laws to provide regulatory authorities any personal
information provided by the Purchaser respecting itself.

 

		6.2	Personal Information

 

Herein, “Personal Information”
means any information about the Purchaser required to be disclosed to a Canadian securities commission or regulatory authority,
whether pursuant to a Canadian securities commission or regulatory authority form or a request made by a Canadian securities commission
or regulatory authority.

 

		6.3	Notification

 

The Purchaser has been notified:

 

		(a)	of the delivery to the Ontario Securities Commission (the “OSC”) of information
with respect to the Purchaser’s full name, head office address and telephone number, the number and type of securities received,
the total value of such securities, the prospectus exemption relied upon by Bionik Canada and the date of distribution (collectively
the “Purchaser Information”),

 

		(b)	that the Purchaser Information is being collected indirectly by the OSC under the authority granted
to it by the Securities Act (Ontario),

 

		(c)	that the Purchaser Information is being collected for the purposes of the administration and enforcement
of the Securities Act (Ontario), and

 

		(d)	that the Administrative Assistant to the Director of Corporate Finance of the OSC can be contacted
at Suite 1903, Box 55, 20 Queen Street West, Toronto, Ontario M5H 3S8 or at 416-593-3684 regarding any questions about the OSC’s
indirect collection of the Purchaser Information,

 

and the Purchaser hereby authorizes
the indirect collection of the Purchaser Information by the OSC.

 

Article 7

NOTICES

 

		7.1	Notices

 

Any notice and other communications
required or permitted to be given pursuant to this agreement shall be sufficiently given if delivered in person or if sent by email
or facsimile transmission (provided such transmission is recorded as being transmitted successfully) to the parties at the following
addresses:

 

    	- 23 -

    	 

    

 

		(i)	In the case of Bionik Canada to the following address:

 

Bionik Laboratories Inc.

483 Bay Street

Office N105

Toronto, ON M5G 2C9

 

Attn:                Peter Bloch

Email:               pb@bioniklabs.com

 

With a copy to (which shall not
constitute notice):

 

Fasken Martineau DuMoulin LLP

333 Bay Street, Suite 2400

Bay Adelaide Centre, Box 20

Toronto, Ontario, Canada M5H 2T6

 

Attn:                Scott Conover

Facsimile:        416 364 7813

Email:               sconover@fasken.com

 

With a copy to (which shall not constitute notice):

 

Ruskin Moscou Faltischek P.C.

East Tower, 15th Floor

RXR Plaza

Uniondale, New York 11556

Attn:                Stephen E. Fox, Esq.

Facsimile:        516 663 6780

Email:               sfox@rmfpc.com

 

or at such other address as the party to
which such notice or other communication is to be given has last notified the party given the same in the manner provided in this
section, and if not given the same shall be deemed to have been received on the date of such delivery or sending.

 

Article 8

GENERAL

 

		8.1	Binding Effect

 

This Agreement shall be binding
upon and enure to the benefit of the parties hereto.

 

    	- 24 -

    	 

    

 

		8.2	Waiver and Modification

 

Bionik US, Purchaser and Bionik
Canada may waive or consent to the modification of, in whole or in part, any inaccuracy of any representation or warranty made
to them hereunder or in any document to be delivered pursuant hereto and may waive or consent to the modification of any of the
covenants or agreements herein contained for their respective benefit or waive or consent to the modification of any of the obligations
of the other parties hereto. No waiver, or consent to the modification of any inaccuracy of any provision of this Agreement constitutes
a waiver of or consent to any proceeding, continuing or succeeding inaccuracy of such provision or of any other provision of this
Agreement. Any waiver or consent to the modification of any of the provisions of this Agreement, to be effective, must be in writing
executed by the party granting such waiver or consent.

 

		8.3	Assignment

 

No party to this Agreement may
assign any of its rights or obligations under this Agreement without the prior written consent of the other party hereto.

 

		8.4	Costs

 

Each of the parties hereto shall
be responsible for their own costs and charges incurred with respect to the transactions contemplated herein, including all costs
and charges incurred prior to the date of this Agreement.

 

		8.5	Time of Essence

 

Time shall be of the essence
of this Agreement.

 

		8.6	Survival

 

The representations and warranties
of each of Bionik US, Purchaser and Bionik Canada contained herein shall survive the execution and delivery of this Agreement.

 

		8.7	Governing Law

 

This Agreement shall be construed
and enforced in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein. Each party hereto
irrevocably attorns and submits to the non-exclusive jurisdiction of the courts of the Province of Ontario with respect to any
matter arising hereunder or related hereto.

 

Each of Bionik US, Purchaser
and Bionik Canada agrees that any action or proceeding arising out of or relating to this Agreement may be instituted in the courts
of Ontario, waives any objection which it may have now or hereafter to the venue of any such action or proceeding, irrevocably
attorns and submits to the non-exclusive jurisdiction of the said courts in any such action or proceeding, agrees to be bound by
any judgement of the said courts and not to seek, and hereby waives, any review of the merits of any such judgement by the courts
of any other jurisdiction, and Bionik US hereby appoints Bionik Canada at its registered office in the Province of Ontario
as attorney for service of process.

 

    	- 25 -

    	 

    

 

		8.8	Severability

 

In the event that any provisions
contained in this Agreement shall be declared invalid, illegal or unenforceable by a court or other lawful authority of competent
jurisdiction, this Agreement shall continue in force with respect to the enforceable provisions and all rights and remedies accrued
under the enforceable provisions shall survive any such declaration, and any non-enforceable provision shall, to the extent permitted
by law, be replaced by a provision which, being valid, comes closest to the intention underlying the invalid, illegal and unenforceable
provision.

 

		8.9	Further Assurances

 

Each party hereto shall, from
time to time, and at all times hereafter, at the request of the other parties hereto, but without further consideration, do all
such further acts and execute and deliver all such further documents and instruments as shall be reasonably required in order to
fully perform and carry out the terms and intent hereof.

 

		8.10	Counterparts and Facsimile Copies

 

This Agreement may be executed
in separate counterparts, and all such counterparts when taken together shall constitute one (1) agreement. The parties shall be
entitled to rely on delivery of a facsimile copy of the executed Agreement and such facsimile copy shall be legally effective to
create a valid and binding Agreement.

 

[Remainder of Page Intentionally Left
Blank]

 

    	- 26 -

    	 

    

 

IN WITNESS WHEREOF the parties have executed this Agreement
as of the date first above written.

 

	BIONIK LABORATORIES INC.	BIONIK LABORATORIES CORP.

 

	Per:	/s/ Peter Bloch	 	Per:	/s/ Austin Kibler
	 	Name:  Peter Bloch	 	 	Name: Austin Kibler
	 	Title: CEO	 	 	Title: Chief Executive Officer

 

	BIONIK ACQUISITION INC.

 

	Per:	 /s/ Peter Bloch	 	 	 
	 	Name:  Peter Bloch	 	 	 
	 	Title: CEO	 	 	 

 

    	- 27 -

    	 

    

 

SCHEDULE “A”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]